Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H10O6 |
| Molecular Weight | 178.14 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O
InChI
InChIKey=PHOQVHQSTUBQQK-SQOUGZDYSA-N
InChI=1S/C6H10O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-5,7-10H,1H2/t2-,3-,4+,5-/m1/s1
| Molecular Formula | C6H10O6 |
| Molecular Weight | 178.14 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.hindawi.com/journals/ecam/2014/169130/
https://www.food.gov.uk/science/additives/enumberlist#h_7
Curator's Comment: description was created based on several sources, including
https://www.hindawi.com/journals/ecam/2014/169130/
https://www.food.gov.uk/science/additives/enumberlist#h_7
Gluconolactone, a lactone of D-glucuronic acid, is a food additive with the E number E575. Gluconolactone is commonly found in honey, fruit juices, wine. In medcine, gluconolactone is used as a component of irrigation solution Renacidin for dissolution of bladder calculi of the struvite or apatite variety, and to prevent or minimize encrustations of indwelling urinary tract catheters.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2364030 Sources: http://www.ncbi.nlm.nih.gov/pubmed/21999455 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | RENACIDIN Approved UseRenacidin Irrigation is indicated for use by local irrigation in the dissolution of renal calculi composed of apatite (a calcium carbonate phosphate compound) or struvite (magnesium ammonium phosphates in patients who are not candidates for surgical removal of the calculi. It may also be used as adjunctive therapy to dissolve residual apatite or struvite calculi and fragments after surgery or to achieve partial dissolution of renal calculi to facilitate surgical removal. Renacidin Irrigation is also indicated for dissolution of bladder calculi of the struvite or apatite variety by local intermittent irrigation through a urethral catheter or cystostomy catheter as an alternative or adjunct to surgical procedures. Renacidin Irrigation is also indicated for use as an intermittent irritating solution to prevent or minimize encrustations of indwelling urinary tract catheters. Since many complications are experienced by patients receiving infusions of Renacidin Irrigation into the renal pelvis, considerable caution must be employed. Additionally, hospitalization is prolonged for days to weeks when chemolytic therapy is used in lieu of, or following surgery. For these reasons, use of this therapy should be reserved for selected patients. Renacidin Irrigation is not indicated for dissolution of calcium oxalate, uric acid or cysteine calculi. Launch Date1990 |
|||
| Secondary | RENACIDIN Approved UseRenacidin Irrigation is indicated for use by local irrigation in the dissolution of renal calculi composed of apatite (a calcium carbonate phosphate compound) or struvite (magnesium ammonium phosphates in patients who are not candidates for surgical removal of the calculi. It may also be used as adjunctive therapy to dissolve residual apatite or struvite calculi and fragments after surgery or to achieve partial dissolution of renal calculi to facilitate surgical removal. Renacidin Irrigation is also indicated for dissolution of bladder calculi of the struvite or apatite variety by local intermittent irrigation through a urethral catheter or cystostomy catheter as an alternative or adjunct to surgical procedures. Renacidin Irrigation is also indicated for use as an intermittent irritating solution to prevent or minimize encrustations of indwelling urinary tract catheters. Since many complications are experienced by patients receiving infusions of Renacidin Irrigation into the renal pelvis, considerable caution must be employed. Additionally, hospitalization is prolonged for days to weeks when chemolytic therapy is used in lieu of, or following surgery. For these reasons, use of this therapy should be reserved for selected patients. Renacidin Irrigation is not indicated for dissolution of calcium oxalate, uric acid or cysteine calculi. Launch Date1990 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Purification and partial characterization of polygalacturonase from Streptomyces lydicus. | 2008-09 |
|
| Fabrication of novel core-shell hybrid alginate hydrogel beads. | 2008-03-03 |
|
| Improvement of P450(BM-3) whole-cell biocatalysis by integrating heterologous cofactor regeneration combining glucose facilitator and dehydrogenase in E. coli. | 2008-02 |
|
| Co-ordinated regulation of gluconate catabolism and glucose uptake in Corynebacterium glutamicum by two functionally equivalent transcriptional regulators, GntR1 and GntR2. | 2008-01 |
|
| Acid gelation properties of heated skim milk as a result of enzymatically induced changes in the micelle/serum distribution of the whey protein/kappa-casein aggregates. | 2007-12-26 |
|
| Remarkable beta-selectivity in the synthesis of beta-1-C-arylglucosides: stereoselective reduction of acetyl-protected methyl 1-C-arylglucosides without acetoxy-group participation. | 2007-12-07 |
|
| A low perfusion rate microreactor for continuous monitoring of enzyme characteristics: application to glucose oxidase. | 2007-11 |
|
| Expedited struvite-stone dissolution using a high-flow low-pressure irrigation system. | 2007-10 |
|
| Short syntheses of gabosine I and gabosine G from delta-D-gluconolactone. | 2007-08-17 |
|
| pH oscillations and bistability in the methylene glycol-sulfite-gluconolactone reaction. | 2007-07-28 |
|
| Crystal structure of Saccharomyces cerevisiae 6-phosphogluconate dehydrogenase Gnd1. | 2007-06-14 |
|
| [The drug release properties of poly (acrylamide-co-itaconate-vinylbenzylglycosylallylamide) hydrogels]. | 2007-06 |
|
| Solubilized micellar calcium induced low methoxyl-pectin aggregation during milk acidification. | 2007-06 |
|
| Acid gelation in heated and unheated milks: interactions between serum protein complexes and the surfaces of casein micelles. | 2007-05-16 |
|
| Crystal structure of intracellular family 1 beta-glucosidase BGL1A from the basidiomycete Phanerochaete chrysosporium. | 2007-04-03 |
|
| Effect of components extracted from okara on the physicochemical properties of soymilk and tofu texture. | 2007-03 |
|
| An organic-based pH oscillator. | 2007-02-01 |
|
| Ultrasonic monitoring of yoghurt formation by using AT-cut quartz: lighting of casein micelles interactions process during the acidification. | 2006-12-22 |
|
| Mechanisms responsible for poor oral bioavailability of paeoniflorin: Role of intestinal disposition and interactions with sinomenine. | 2006-12 |
|
| Cellobiase from Termitomyces clypeatus: activity and secretion in presence of glycosylation inhibitors. | 2006-11 |
|
| A novel technique for differentiation of proteins in the development of acid gel structure from control and heat treated milk using confocal scanning laser microscopy. | 2006-11 |
|
| Adsorption and aggregation properties of heterogemini surfactants containing a quaternary ammonium salt and a sugar moiety. | 2006-10-24 |
|
| Study of the effect of soy proteins on the acid-induced gelation of casein micelles. | 2006-10-18 |
|
| Starter bacteria are the prime agents of lipolysis in cheddar cheese. | 2006-10-18 |
|
| Soluble aldose sugar dehydrogenase from Escherichia coli: a highly exposed active site conferring broad substrate specificity. | 2006-10-13 |
|
| Addition of pectin and soy soluble polysaccharide affects the particle size distribution of casein suspensions prepared from acidified skim milk. | 2006-08-23 |
|
| Tetranuclear copper(II) complexes bridged by alpha-D-glucose-1-phosphate and incorporation of sugar acids through the Cu4 core structural changes. | 2006-08-21 |
|
| Functional and structural properties of 2S soy protein in relation to other molecular protein fractions. | 2006-08-09 |
|
| Divergent synthesis of L-sugars and L-iminosugars from D-sugars. | 2006-07-24 |
|
| Complex coacervation between beta-lactoglobulin and Acacia gum: a nucleation and growth mechanism. | 2006-07-15 |
|
| Formation of stable nanoparticles via electrostatic complexation between sodium caseinate and gum arabic. | 2006-06-05 |
|
| Potentially implantable miniature batteries. | 2006-06 |
|
| Redox polymer and probe DNA tethered to gold electrodes for enzyme-amplified amperometric detection of DNA hybridization. | 2006-04-15 |
|
| Testing electrostatic complementarity in enzyme catalysis: hydrogen bonding in the ketosteroid isomerase oxyanion hole. | 2006-04 |
|
| Discovering functional gene expression patterns in the metabolic network of Escherichia coli with wavelets transforms. | 2006-03-08 |
|
| Investigations on foamability of surface-chemically pure aqueous solutions of functionalized alkylaldonamides. | 2006-02-15 |
|
| Redox mediation at 11-mercaptoundecanoic acid self-assembled monolayers on gold. | 2006-02-09 |
|
| Effect of insulin on small intestinal transit in normal mice is independent of blood glucose level. | 2006-02-01 |
|
| Purification and characterization of an intracellular beta-glucosidase from the methylotrophic yeast Pichia pastoris. | 2005-12 |
|
| Stabilization of caseinate-covered oil droplets during acidification with high methoxyl pectin. | 2005-11-02 |
|
| Microwave activation of the electro-oxidation of glucose in alkaline media. | 2005-10-21 |
|
| Effects of two types of emulsifying salts on the functionality of nonfat pasta filata cheese. | 2005-10 |
|
| The effects of various organic acids on phytate phosphorus utilization in chicks. | 2005-09 |
|
| Isolation of a human intestinal bacterium that transforms mangiferin to norathyriol and inducibility of the enzyme that cleaves a C-glucosyl bond. | 2005-09 |
|
| Enzyme-assisted reforming of glucose to hydrogen in a photoelectrochemical cell. | 2005-06-18 |
|
| Dynamic simulation of red blood cell metabolism and its application to the analysis of a pathological condition. | 2005-05-09 |
|
| Adsorption behavior of surface chemically pure N-cycloalkylaldonamides at the air/water interface. | 2005-04-26 |
|
| Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. | 2005-04-20 |
|
| Adsorption behavior of surface-chemically pure N-alkyl-N-(2-hydroxyethyl)aldonamides at the air/water interface. | 2004-03-02 |
|
| Simultaneous determination of gluconolactone, galactonolactone and galactitol in urine by reversed-phase liquid chromatography: application to galactosemia. | 1991-10-04 |
Patents
Sample Use Guides
For dissolution of bladder calculi, 30 mL (one container) of Renacidin should be instilled into the bladder via a urethral catheter or cystostomy tube. For prevention of encrustations in urethral catheters and cystostomy tube, 30 mL (one container) of Renacidin should be instilled into the urethral catheter or cystostomy tube. As a food additive, gluconolactone is administered orally.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17949316
Chemolysis rate was tested using an in-vitro urinary-tract model. A laboratory-proved large human struvite stone was divided into 3.5-g fragments, which were placed in the model. In the experimental group, Renacidin irrigation was performed through the high-flow low-pressure irrigation system. In the control group, Renacidin solution was infused at 120 mL/hour through a nephrostomy tube. The overall chemolysis rates with the high-flow low-pressure irrigation and control systems were 0.12 g/hr and 0.06 g/hr, respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:29:46 GMT 2025
by
admin
on
Mon Mar 31 18:29:46 GMT 2025
|
| Record UNII |
WQ29KQ9POT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
JECFA EVALUATION |
INS-575
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-575
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
NDF-RT |
N0000175534
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
CFR |
21 CFR 184.1318
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
NCI_THESAURUS |
C275
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
NDF-RT |
N0000175835
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
DSLD |
4056 (Number of products:1)
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
FDA ORPHAN DRUG |
40189
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
16217
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
488
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
WQ29KQ9POT
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
GLUCONO DELTA-LACTONE
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
m5763
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID0026549
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
5144
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
C010730
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
DB04564
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200829
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
202-016-5
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
7027
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
100000144440
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
C47549
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
34393
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
WQ29KQ9POT
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
25842
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | RxNorm | ||
|
758238
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
SUB120981
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
1294150
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
90-80-2
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|